(Total Views: 337)
Posted On: 11/13/2018 8:44:56 AM
Post# of 72451
CONCLUSIONS
• Brilacidin exhibited favorable efficacy in UP/UPS (IBD) across 3 dose-escalation cohorts (50 mg, 100 mg, 200 mg as retention enema)
- Proof-of-Concept achieved with current simple water formulation*
-Clinical Remission (with endoscopic response) in at least half of subjects in each cohort
-Improved Quality-of-Life
• Safety data show Brilacidinwell-tolerated
• PK demonstrates limited systemic absorption by local route of administration
Data support Brilacidin clinical efficacy with local treatment
*Formulation development plans for Brilacidininclude tablets for oral dosing of more extensive Ulcerative Colitis and Crohn’s Disease and foam and/or gel for UP/UPS
• Brilacidin exhibited favorable efficacy in UP/UPS (IBD) across 3 dose-escalation cohorts (50 mg, 100 mg, 200 mg as retention enema)
- Proof-of-Concept achieved with current simple water formulation*
-Clinical Remission (with endoscopic response) in at least half of subjects in each cohort
-Improved Quality-of-Life
• Safety data show Brilacidinwell-tolerated
• PK demonstrates limited systemic absorption by local route of administration
Data support Brilacidin clinical efficacy with local treatment
*Formulation development plans for Brilacidininclude tablets for oral dosing of more extensive Ulcerative Colitis and Crohn’s Disease and foam and/or gel for UP/UPS
(5)
(0)
